At the end of January, two vaccines from the Covid of domestic production are available to the Russians - the “satellite V” of the Hamalei Institute and the “Epivaccoron” of the Center Center Center. Vaccination is the first most massive.

Two more vaccines await registration in the Russian Ministry of Health: the domestic “covivak” of the Center for the Chumakov RAS and the Chinese “Connection”. Read in detail about these and other candidates vaccines in our guide.

"Satellite V" ("Gam-kovid-Wak")

Country: Russia.

Developer: NIC epidemiology and microbiology. N.F. Gamalei of the Ministry of Health of Russia.

Vaccine type: two -component vector vaccine. The vaccine is administered twice, with an interval of three weeks.

How it works: the propagation gene was removed from adenovirus and a gene was placed in it, which encodes the coronavirus spike. With the help of S-protein, coronavirus enters the cage.

Adenovirus, which is engaged in the transportation of "training material" for the immune system, is well familiar to the person - it causes ordinary SARS. The vaccine is two -century, because it uses two types of adenovirus: two injections are made so that at least one of them probably pass through the immune defense of the body.

Storage conditions: -18 ℃.

Efficiency: according to the results of intermediate studies, the effectiveness of the “satellite V” is 91.4%, against severe cases of the disease - 100%. Immunity is produced three weeks after the introduction of the second component of the vaccine.

Side effects: chills, fever, headache, as well as a decrease in appetite and an increase in lymph nodes.

Vaccination in Russia: began on December 5, 2020. Vaccination can be done for free.

The need for revaccination: it is expected that immunity will be formed for two years.

Stage: Clinical studies of the third phase continue. The vaccine received temporary registration of the Ministry of Health of Russia on August 8, 2020. In early January, the Ministry of Health issued permission to the Hamalea Center for Clinical Testing of a one -component version of the Satellite V drug, the satellite Light vaccine.

Clinical studies: “satellite V” is checked using a double, blind randomized placebo-controlled clinical study*. The number of participants in clinical trials with the permission of the Ministry of Health is reduced from 40,000 to 31,000. Of these, 25% will receive placebo. The press service of the RDIP, who oversees the creation of the vaccine, did not answer the VTIMES question about the publication of the final results of the third phase in international medical journals.

Manufacturers: Binnopharm, Generium, Biocad, the Medgamal branch NICEM named after N.F. Gamaley. Later, R-Farm, Pharmacintesis may join them.

According to Prime Minister Mikhail Mishustin, it is planned to produce almost 6.5 million doses of vaccine per month.

*Golden Study Standard

Vaccine of the Center "Vector" ("Epivaccoron")

Country: Russia.

Developer: State Scientific Center for Virology and Biotechnology "Vector" of Rospotrebnadzor.

Type of vaccine: a vaccine based on peptide antigens. It is introduced twice, intramuscularly with an interval of three weeks.

How it works: the vaccine consists of short sections of the viral protein - peptides necessary for the formation of an immune response.

Storage conditions: 2–8 ° C (conditions of a conventional refrigerator).

Efficiency: the intermediate report will be released in early February. Cellular immunity is produced a month and a half after the introduction of the vaccine.

Side effects: short -term pain in the injection site.

The need for revaccination: every three years.

Stage: Clinical studies are underway. The vaccine received temporary registration of the Ministry of Health on October 13.

Vaccination in Russia: It has begun. Vaccination can be done for free.

Clinical studies: Two studies are conducted. The first is a multicenter, double, blind placebo-controlled comparative randomized study* with the participation of 3,000 volunteers from the age of 18 (third phase). It is planned to be completed at the end of July 2021.

The second is an open study of the safety, reactogenicity and immunogenicity of the vaccine with the participation of volunteers aged 60 and older (third phase). It will end at the end of January, and observation of volunteers will continue for six months.

Manufacturers: State Scientific Center for Virology and Biotechnology "Vector" of Rospotrebnadzor. The company "Gerofarm" will produce one of the key components of the vaccine-the carrier protein. The large -scale production of the vaccine will be deployed in February.

*Golden Study Standard

"Convention" (AD5-NCOV)

Country: China.

Developer: Cansino Biologics Inc.

Vaccine type: recombinant vaccine. Introduce once.

How it works: the vaccine uses the platform of the adenovirus vector of a person carrying s-beads of coronavirus. This vector acts as a “delivery tool”, and the S-White is an antigen to which the immune response is produced.

Storage conditions: 2–8 ℃ (conditions of ordinary refrigerator).

Efficiency: the intermediate results of the local clinical study of the third phase showed the effectiveness of the vaccine at the level of 92.5%. The data of 200 volunteers out of 500 spaceds were analyzed. Cellular immunity occurs in the first 14 days.

Side effects: 34.2% of volunteers had a small temperature, headache, joint pain or muscles, fatigue, which took place during the first few days.

Vaccination in Russia: did not begin.

The need for revaccination: no data.

Stage: In Russia, the vaccine passes through the third phase of international clinical trials, there is a set of volunteers. Documents for registration were submitted to the Ministry of Health of Russia.

Clinical studies: international, double, blind randomized placebo-controlled study*. In total, more than 40,000 volunteers will take part in it, 8,000 of them will be from Russia.

Manufacturer: After registration of the vaccine, the Russian company Petrovax is ready to launch the production of the vaccine at the factory in the Moscow region. The start of production was scheduled for 2021, VTIMES said in the company's press service.

*Golden Study Standard

Vaccine of the center named after Chumakov RAS ("Covivak")

Country: Russia.

Developer: Federal Scientific Center for Research and Development of Immunobiological Preparations named after M.P. Chumakova RAS.

Type of vaccine: whole -cylinder.

How it works: to develop immunity, the “killed” is introduced, but the virus preserving the antigenic properties.

Storage conditions: 2–8 ° C (conditions of a conventional refrigerator).

Efficiency: no data. Introduced twice, with an interval of 2-3 weeks.

Side effects: no unwanted phenomena after vaccination of 200 volunteers were detected.

The need for revaccination: no data.

Stage: Clinical studies of the second stage on healthy volunteers aged 18 to 60 years end in January. The third test phase is expected in March 2021. It is planned to include about 3,000 people. Deputy Prime Minister Tatyana Golikova expects to register a vaccine in mid-February.

Vaccination in Russia: did not begin. The release of the first series of the vaccine is planned in the second half of March.

Clinical research: Research design is unknown.

Manufacturer: Center named after Chumakova prepared a production site. The company is negotiating with Nanolek, VTIMES reported in the press service of the latter. The first batch of the vaccine from the center named after Chumakova will contain 100,000 doses. The production site will produce 10 million doses per year.

Oxford vaccine (AZD1222)

Country: UK.

Developer: ASTRAZENECA together with Oxford University.

Type of vaccine: two -component vaccine based on the adenovirus vector. Two doses are administered.

How it works: a weakened version of the SARSI SHIMPPANZE virus, which cannot multiply, contains the genetic material of the coronavirus spike. After vaccination, the synthesis of the surface spike -shaped protein occurs and the immune response is formed.

Storage conditions: 2–8 ℃, the vaccine is suitable for six months.

Efficiency: according to the intermediate analysis of the third phase of the study published in The Lancet magazine, when the volunteers of two complete doses of the vaccine are effective in 62.1% of people, and with a half and full dose in 90% of the study participants. Intermediate results are based on data from clinical research conducted in the UK and Brazil with the participation of 11,636 volunteers, among which 131 cases of infection Covid-19 were identified.

Side effects: temporary pain at the injection, weakness and fatigue, headache, fever and muscle pain.

Vaccination in Russia: it has not begun, there are no approximate dates.

The need for revaccination: no data.

Stage: Clinical studies of vaccines continue throughout the world: in the UK, USA, Brazil, South Africa, Japan, Kenya. It is planned to conduct studies of the Oxford vaccine, combined with another vaccine. According to the global database of clinical testing Clinical Trita, the test in Russia was suspended.

Clinical studies: double, blind, multicenter randomized controlled research*, in which up to 60,000 volunteers of different age, racial, ethnic and geographical groups participate.

Manufacturer: In Russia, the R-Farm company will be produced by the vaccine.

*Golden Study Standard

Do developers of other vaccines from Covida plan to go to Russia?

The American-German matrix RNA vaccine from Pfizer & Biontech: Pfizer is considering the possibility of applying for registration of a Candidate vaccine against Covid-19 in Russia, but there are no exact dates yet.

The American matrix RNA-Vaccine MRNA-1273 from Moderna: at the end of December, the branch of the Israeli Hadassah hospital in Skolkovo, who has the right to use drugs unregistered in Russia, announced negotiations to the supply of Pfizer and Moderna vaccines to Russia. The clinic was entered by those who want to vaccinate in a “waiting sheet”.

Later, Roszdravnadzor said that it was prohibited to import vaccines that have not passed state registration in the country. This also applies to a special zone - the international medical cluster in Skolkovo. On the Hadassah hot line, the VTIMES correspondent reported that the entry in the "waiting sheet" for vaccination from Covid was stopped. Moderna has not yet answered the publication about plans to enter Russia.

The American Janssen American Vaccine on the basis of adenovirus type 26 (Johnson & Johnson): according to the managing director of Jansssen Russia and the CIS Katerina Pogodina, at this stage the company is focused on the completion of clinical studies of the vaccine.

The American recombinant vaccine from MSD: January 25, the company announced that it stops developing two of its experimental vaccines against Covid, since they could not cause an immune response comparable to existing vaccines or response after a natural infection. In September, the Mariinsky hospital in St. Petersburg announced a set of volunteers for testing the MSD vaccine. At the moment, their search is completed, the clinic reported. The Russian representative of MSD refused to comment.

The Franco-British adjuvant recombinant vaccine from Sanofi/GSK: there is no data on access to Russia. Sanofi did not comment on the possible supply of vaccines to Russia.

The British British American Tobacco vaccine, created using tobacco raw materials: the Bat Vtimes global press service said the clinical study of the first phase is still being held in the United States. In later stages, more volunteers will be required, but the location of these studies has not yet been determined. The company assured that in case of successful results of the vaccine can be provided to any government. And its accessibility will depend on the approval of national regulatory authorities and public procurement.

Chinese inactivated Coronavac vaccine by Sinovac Biotech
Chinese inactivated vaccine from China National Biotec Group, Sinopharm units
American recombinant protein vaccine novavax
American DNA-4800 DNA-4800

There is no data on the release of these vaccines to Russia. The companies did not respond to the VTIMES request.

In the preparation of the material, the data provided by the VTIMES by the press services "Petrovax", "Astrazenka", Pfizer, Sanofi, MSD, BAT and Rospotrebnadzor; as well as information from the sites of pharmaceutical companies and resources "Stopkoronavirus", Clinical Tritals; Materials of Bloomberg, RBC, TASS, Vademecum, Interfax and Russian Newspaper.

What is known about Kovid vaccines - vtimes